On July 13, 2026, FDA approved once-weekly subcutaneous lecanemab-irmb, branded LEQEMBI IQLIK, as a starting dose for early Alzheimer's disease, according to the FDA approval notice from Eisai and Biogen. For people with mild cognitive impairment due to Alzheimer's, it means treatment can now begin at home without starting with infusions.
Mild cognitive impairment means memory or thinking changes that are noticeable but do not yet block daily life. Early Alzheimer's here means mild cognitive impairment or mild dementia due to Alzheimer's disease. The new option covers starting treatment, not just staying on it.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Eisai — Use this primary source to verify the official guidance.
- Read the official guidance from Medscape — Use this primary source to verify the official guidance.
Table of Contents
- Who is this news for?
- How does at-home starting treatment work?
- What safety steps still apply?
- What changed from infusion treatment?
Who is this news for?
This starting dose is for adults with early Alzheimer's disease. That group includes mild cognitive impairment or mild dementia due to Alzheimer's. If a diagnosis is uncertain, a clinician must sort out the cause first.
It does not widen who can take lecanemab. It changes how eligible people can begin it. People already receiving infusions should ask their care team whether a change makes sense. Do not stop or switch treatment on your own.
How does at-home starting treatment work?
The starting regimen is 500 mg once per week, given as two back-to-back 250-mg autoinjector shots, according to the dosing details from Eisai. Each injection takes about 15 seconds. A care partner can help, but training comes first.
Treatment must start under a health professional. That professional must directly watch at least two weekly doses in a row and confirm the patient or caregiver can inject safely before home use. Home use begins only after that check is passed.
- Start with clinician teaching and supervised shots
- Show safe autoinjector use for two straight weeks
- Move to weekly home shots only when cleared
- Keep follow-up visits and contact plans in place
What safety steps still apply?
An at-home shot does not mean treatment without oversight. Brain MRI checks for amyloid-related imaging abnormalities remain required, with a baseline scan plus planned follow-up scans. Medscape reported that caregiver training and clinician oversight also stay required whatever the route in its Alzheimer's care analysis.
Those MRI scans look for swelling or bleeding linked to anti-amyloid drugs. Report severe headache, vision change, confusion, dizziness, or trouble walking right away. Keep a list of current drugs, allergies, and emergency contacts where caregivers can find it.
What changed from infusion treatment?
Before, IV lecanemab was 10 mg/kg every two weeks over about one hour. In August 2025, FDA allowed weekly 360-mg subcutaneous maintenance only after 18 months of IV treatment. The July 2026 action removed that infusion-start rule.
The approval rested on evidence that weekly shots give similar drug exposure and amyloid removal as IV treatment. Eisai planned U.S. launch for initiation in late August 2026 through specialty pharmacy. Ask the prescribing clinic which pharmacy will dispense it and what teaching visits are booked.
You Might Also Like
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: A Source-Checked Research Briefing for People With Mild Cognitive Impairment
- NHATS and NSOC Dementia Care Data Priorities in 2026: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
